Derivative exercise or conversion — not an open-market buy.
Traded Apr 7, 2026 · Filed Apr 8, 2026
Sold under a plan set up in advance, so the timing wasn't a fresh decision
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$304,013
Shares × reported transaction price
49 days after results of Feb 17, 2026, 28 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $158.87 on Apr 7, 2026, 19% above its 52-week low and 20% below its high, after an 8% drop over the previous 30 trading days
52-week range $133.36 (Apr 8, 2025) to $199.55 (Nov 4, 2025), 39% of the way up, from 250 adjusted closes. 30 trading days earlier: $172.00 on Feb 23, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.5% | +3.2% | -2.7% |
| 30 days | -18.0% | +8.7% | -26.7% |
| 90 days | -31.1% | +9.6% | -40.8% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
A board member of Leidos sold $197K of Leidos shares. Nobody planned it ahead of time.